|Application ||WB, IHC-P, IF, FC, E|
|Calculated MW||48507 Da|
|Antigen Region||396-426 aa|
|Other Names||Urokinase-type plasminogen activator, U-plasminogen activator, uPA, Urokinase-type plasminogen activator long chain A, Urokinase-type plasminogen activator short chain A, Urokinase-type plasminogen activator chain B, PLAU|
|Target/Specificity||This Urokinase (PLAU) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 396-426 amino acids from the C-terminal region of human Urokinase (PLAU).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Urokinase (PLAU) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.|
|Tissue Location||Expressed in the prostate gland and prostate cancers.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002).
Sperl, S., et al., Proc. Natl. Acad. Sci. U.S.A. 97(10):5113-5118 (2000).
Turkmen, B., et al., Electrophoresis 18(5):686-689 (1997).
Conne, B., et al., Thromb. Haemost. 77(3):434-435 (1997).
Yoshimoto, M., et al., Biochim. Biophys. Acta 1293(1):83-89 (1996).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.